Selecting an Appropriate BTK Inhibitor for the Treatment of Relapsed CLL

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.

Four trajectories of change were identified in FACT-PWB score, with large patient groups experiencing little to no change or slight declines in PWB.